In Japanese people living with T2D, tirzepatide decreased HbA1c by −2.8% after 52 weeks of treatment, relative to −1.3% in dulaglutide treated controls [975], and similar effects were observed in the SURPASS J-combo trial, in which tirzepatide was given as add-on therapy to sulfonylureas, biguanides, α-glucosidase inhibitors, thiazolidinedione, glinides, or SGLT2 inhibitors in Japanese people with poorly controlled T2D [976]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.